Published in Eur J Hum Genet on April 15, 2009
Advances in clinical and molecular understanding of the FMR1 premutation and fragile X-associated tremor/ataxia syndrome. Lancet Neurol (2013) 2.41
Murine hippocampal neurons expressing Fmr1 gene premutations show early developmental deficits and late degeneration. Hum Mol Genet (2010) 1.95
FMR1 CGG allele size and prevalence ascertained through newborn screening in the United States. Genome Med (2012) 1.85
Advances in understanding the molecular basis of FXTAS. Hum Mol Genet (2010) 1.83
Fragile X and autism: Intertwined at the molecular level leading to targeted treatments. Mol Autism (2010) 1.57
Prevalence of CGG expansions of the FMR1 gene in a US population-based sample. Am J Med Genet B Neuropsychiatr Genet (2012) 1.49
Emerging topics in FXTAS. J Neurodev Disord (2014) 1.47
Neuropathological, clinical and molecular pathology in female fragile X premutation carriers with and without FXTAS. Genes Brain Behav (2012) 1.44
Widespread non-central nervous system organ pathology in fragile X premutation carriers with fragile X-associated tremor/ataxia syndrome and CGG knock-in mice. Acta Neuropathol (2011) 1.39
Molecular Inconsistencies in a Fragile X Male with Early Onset Ataxia. Genes (Basel) (2016) 1.38
Co-occurring diagnoses among FMR1 premutation allele carriers. Clin Genet (2010) 1.33
The unstable repeats--three evolving faces of neurological disease. Neuron (2013) 1.26
Premutation CGG-repeat expansion of the Fmr1 gene impairs mouse neocortical development. Hum Mol Genet (2010) 1.24
Signaling defects in iPSC-derived fragile X premutation neurons. Hum Mol Genet (2012) 1.19
Evidence for RNA-mediated toxicity in the fragile X-associated tremor/ataxia syndrome. Future Neurol (2009) 1.17
Clustered burst firing in FMR1 premutation hippocampal neurons: amelioration with allopregnanolone. Hum Mol Genet (2012) 1.15
Psychological symptoms correlate with reduced hippocampal volume in fragile X premutation carriers. Am J Med Genet B Neuropsychiatr Genet (2010) 1.14
Exploring the adult life of men and women with fragile X syndrome: results from a national survey. Am J Intellect Dev Disabil (2011) 1.14
Fragile X-associated disorders: a clinical overview. J Neurol (2011) 1.13
Histone deacetylases suppress CGG repeat-induced neurodegeneration via transcriptional silencing in models of fragile X tremor ataxia syndrome. PLoS Genet (2010) 1.11
Early mitochondrial abnormalities in hippocampal neurons cultured from Fmr1 pre-mutation mouse model. J Neurochem (2012) 1.10
Enhanced asynchronous Ca(2+) oscillations associated with impaired glutamate transport in cortical astrocytes expressing Fmr1 gene premutation expansion. J Biol Chem (2013) 1.04
Immune-mediated disorders among women carriers of fragile X premutation alleles. Am J Med Genet A (2012) 1.04
Clinical involvement in daughters of men with fragile X-associated tremor ataxia syndrome. Clin Genet (2010) 1.04
Fibromyalgia in fragile X mental retardation 1 gene premutation carriers. Rheumatology (Oxford) (2011) 1.02
Hypertension in FMR1 premutation males with and without fragile X-associated tremor/ataxia syndrome (FXTAS). Am J Med Genet A (2012) 1.00
Rare intranuclear inclusions in the brains of 3 older adult males with fragile x syndrome: implications for the spectrum of fragile x-associated disorders. J Neuropathol Exp Neurol (2011) 1.00
Daily health symptoms of mothers of adolescents and adults with fragile x syndrome and mothers of adolescents and adults with autism spectrum disorder. J Autism Dev Disord (2012) 0.99
Current Gaps in Understanding the Molecular Basis of FXTAS. Tremor Other Hyperkinet Mov (N Y) (2012) 0.99
Neuropathic pain-like alterations in muscle nociceptor function associated with vibration-induced muscle pain. Pain (2010) 0.99
Fragile X-associated tremor/ataxia syndrome. Ann N Y Acad Sci (2015) 0.98
Broad clinical involvement in a family affected by the fragile X premutation. J Dev Behav Pediatr (2009) 0.94
Associated features in females with an FMR1 premutation. J Neurodev Disord (2014) 0.94
Prevalence and risk of migraine headaches in adult fragile X premutation carriers. Clin Genet (2013) 0.93
Autoimmune disease in mothers with the FMR1 premutation is associated with seizures in their children with fragile X syndrome. Hum Genet (2010) 0.92
Newborn screening and cascade testing for FMR1 mutations. Am J Med Genet A (2012) 0.91
Neural substrates of executive dysfunction in fragile X-associated tremor/ataxia syndrome (FXTAS): a brain potential study. Cereb Cortex (2012) 0.90
Depression and anxiety symptoms among women who carry the FMR1 premutation: impact of raising a child with fragile X syndrome is moderated by CRHR1 polymorphisms. Am J Med Genet B Neuropsychiatr Genet (2012) 0.89
Mouse models of the fragile X premutation and fragile X-associated tremor/ataxia syndrome. J Neurodev Disord (2014) 0.89
PSYCHIATRIC DISORDERS ASSOCIATED WITH FXTAS. Curr Psychiatry Rev (2015) 0.87
Memantine for fragile X-associated tremor/ataxia syndrome: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry (2014) 0.86
EMQN best practice guidelines for the molecular genetic testing and reporting of fragile X syndrome and other fragile X-associated disorders. Eur J Hum Genet (2014) 0.86
Fragile x-associated tremor ataxia syndrome: the expanding clinical picture, pathophysiology, epidemiology, and update on treatment. Tremor Other Hyperkinet Mov (N Y) (2012) 0.86
The cognitive neuropsychological phenotype of carriers of the FMR1 premutation. J Neurodev Disord (2014) 0.85
FMRpolyG-positive inclusions in CNS and non-CNS organs of a fragile X premutation carrier with fragile X-associated tremor/ataxia syndrome. Acta Neuropathol Commun (2014) 0.85
Assessment of patient and caregiver needs in fragile X-associated tremor/ataxia syndrome by utilizing Q-sort methodology. Aging Ment Health (2010) 0.85
Epigenetics in nucleotide repeat expansion disorders. Semin Neurol (2012) 0.85
Ages of Onset of Mood and Anxiety Disorders in Fragile X Premutation Carriers. Curr Psychiatry Rev (2013) 0.84
Caregiver Burden in Fragile X Families. Curr Psychiatry Rev (2013) 0.84
Unstable mutations in the FMR1 gene and the phenotypes. Adv Exp Med Biol (2012) 0.84
Genes and genetic testing in hereditary ataxias. Genes (Basel) (2014) 0.83
Dysregulated iron metabolism in the choroid plexus in fragile X-associated tremor/ataxia syndrome. Brain Res (2014) 0.83
A Quantitative Assessment of Tremor and Ataxia in Female FMR1 Premutation Carriers Using CATSYS. Curr Gerontol Geriatr Res (2011) 0.82
Repeat-mediated genetic and epigenetic changes at the FMR1 locus in the Fragile X-related disorders. Front Genet (2014) 0.82
Molecular Advances Leading to Treatment Implications for Fragile X Premutation Carriers. Brain Disord Ther (2014) 0.81
Reversibility of neuropathology and motor deficits in an inducible mouse model for FXTAS. Hum Mol Genet (2015) 0.81
Caregiver opinions about fragile X population screening. Genet Med (2011) 0.81
Distribution and frequency of intranuclear inclusions in female CGG KI mice modeling the fragile X premutation. Brain Res (2012) 0.80
Screening for the presence of FMR1 premutation alleles in a Spanish population with fibromyalgia. Clin Rheumatol (2012) 0.80
Trajectory and Predictors of Depression and Anxiety Disorders in Mothers With the FMR1 Premutation. Biol Psychiatry (2015) 0.80
Fragile X syndrome: an aging perspective. Dev Disabil Res Rev (2013) 0.79
Evidence of an age-related correlation of ovarian reserve and FMR1 repeat number among women with "normal" CGG repeat status. J Assist Reprod Genet (2015) 0.79
COGNITIVE DYSFUNCTION IN FMR1 PREMUTATION CARRIERS. Curr Psychiatry Rev (2013) 0.79
Towards an Understanding of Neuropsychiatric Manifestations in Fragile X Premutation Carriers. Future Neurol (2014) 0.78
Offering fragile X syndrome carrier screening: a prospective mixed-methods observational study comparing carrier screening of pregnant and non-pregnant women in the general population. BMJ Open (2013) 0.78
Developmental profiles of infants with an FMR1 premutation. J Neurodev Disord (2016) 0.77
Postpartum Depression in Women with the FMR1 Premutation. Curr Psychiatry Rev (2015) 0.77
Addictive substances may induce a rapid neurological deterioration in fragile X-associated tremor ataxia syndrome: A report of two cases. Intractable Rare Dis Res (2014) 0.77
Fragile X-associated tremor/ataxia syndrome - features, mechanisms and management. Nat Rev Neurol (2016) 0.77
Immune dysregulation as a cause of autoinflammation in fragile X premutation carriers: link between FMRI CGG repeat number and decreased cytokine responses. PLoS One (2014) 0.77
Maternal Consequences of the Detection of Fragile X Carriers in Newborn Screening. Pediatrics (2015) 0.76
Reproductive and gynecologic care of women with fragile X primary ovarian insufficiency (FXPOI). Menopause (2016) 0.76
A genetic study of the FMR1 gene in a Sardinian multiple sclerosis population. Neurol Sci (2015) 0.75
Monoclonal Gammopathy of Undetermined Significance (MGUS) in a Man with Fragile X-associated Tremor/Ataxia Syndrome. Case Rep Genet (2011) 0.75
Current research, diagnosis, and treatment of fragile X-associated tremor/ataxia syndrome. Intractable Rare Dis Res (2014) 0.75
Fragile X-Associated Tremor/Ataxia Syndrome (FXTAS) Motor Dysfunction Modeled in Mice. Cerebellum (2016) 0.75
Fragile X syndrome: a review of clinical and molecular diagnoses. Ital J Pediatr (2017) 0.75
Improving Health Education for Women Who Carry an FMR1 Premutation. J Genet Couns (2015) 0.75
Molecular Correlates and Recent Advancements in the Diagnosis and Screening of FMR1-Related Disorders. Genes (Basel) (2016) 0.75
The fragile X mental retardation 1 gene (FMR1): historical perspective, phenotypes, mechanism, pathology, and epidemiology. Clin Neuropsychol (2016) 0.75
Endocrine Dysfunction in Female FMR1 Premutation Carriers: Characteristics and Association with Ill Health. Genes (Basel) (2016) 0.75
A novel assay for evaluating fragile X locus repeats. J Mol Diagn (2011) 0.75
Associated Clinical Disorders Diagnosed by Medical Specialists in 188 FMR1 Premutation Carriers Found in the Last 25 Years in the Spanish Basque Country: A Retrospective Study. Genes (Basel) (2016) 0.75
Reduced vagal tone in women with the FMR1 premutation is associated with FMR1 mRNA but not depression or anxiety. J Neurodev Disord (2017) 0.75
Fragile X premutation in women: recognizing the health challenges beyond primary ovarian insufficiency. J Assist Reprod Genet (2016) 0.75
Risk Factors for Cognitive Impairment in Fragile X-Associated Tremor/Ataxia Syndrome. J Geriatr Psychiatry Neurol (2016) 0.75
Don't miss patients with atypical FMR1 mutations: dysmorphism and clinical features in a boy with a partially methylated FMR1 full mutation. Eur J Pediatr (2014) 0.75
Screening for intermediate CGG alleles of FMR1 gene in male Iranian patients with Parkinsonism. Neurol Sci (2016) 0.75
Implications of the FMR1 Premutation for Children, Adolescents, Adults, and Their Families. Pediatrics (2017) 0.75
Fragile X-Associated Diminished Ovarian Reserve and Primary Ovarian Insufficiency from Molecular Mechanisms to Clinical Manifestations. Front Mol Neurosci (2017) 0.75
Fragile X-Associated Tremor/Ataxia Syndrome: From Molecular Pathogenesis to Development of Therapeutics. Front Cell Neurosci (2017) 0.75
The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum (1995) 7.97
The Colorado thyroid disease prevalence study. Arch Intern Med (2000) 7.84
Elevated levels of FMR1 mRNA in carrier males: a new mechanism of involvement in the fragile-X syndrome. Am J Hum Genet (2000) 6.73
Intention tremor, parkinsonism, and generalized brain atrophy in male carriers of fragile X. Neurology (2001) 6.55
Penetrance of the fragile X-associated tremor/ataxia syndrome in a premutation carrier population. JAMA (2004) 4.88
The fragile-X premutation: a maturing perspective. Am J Hum Genet (2004) 3.89
Fragile X premutation is a significant risk factor for premature ovarian failure: the International Collaborative POF in Fragile X study--preliminary data. Am J Med Genet (1999) 3.82
Expanded clinical phenotype of women with the FMR1 premutation. Am J Med Genet A (2008) 2.91
Prevalence of carriers of premutation-size alleles of the FMRI gene--and implications for the population genetics of the fragile X syndrome. Am J Hum Genet (1995) 2.77
Premutation and intermediate-size FMR1 alleles in 10572 males from the general population: loss of an AGG interruption is a late event in the generation of fragile X syndrome alleles. Hum Mol Genet (2002) 2.77
Fragile X-associated tremor/ataxia syndrome: clinical features, genetics, and testing guidelines. Mov Disord (2007) 2.68
Heterozygous fragile X female: historical, physical, cognitive, and cytogenetic features. Am J Med Genet (1991) 2.29
Clinical involvement and protein expression in individuals with the FMR1 premutation. Am J Med Genet (2000) 2.24
Fragile-X syndrome and fragile X-associated tremor/ataxia syndrome: two faces of FMR1. Lancet Neurol (2007) 2.00
Hypothalamic-pituitary-adrenal axis perturbations in patients with fibromyalgia. Arthritis Rheum (1994) 1.97
Aging in individuals with the FMR1 mutation. Am J Ment Retard (2004) 1.68
Implications of the FMR1 gene in menopause: study of 147 Spanish women. Menopause (2001) 1.58
Evidence for, and a spectrum of, neurological involvement in carriers of the fragile X pre-mutation: FXTAS and beyond. Clin Genet (2005) 1.37
Evidence of depressive symptoms in fragile-X syndrome premutated females. Psychiatr Genet (2008) 1.33
Neurobehavioral phenotype in carriers of the fragile X premutation. Am J Med Genet (2001) 1.28
Incidence of fragile X in 5,000 consecutive newborn males. Genet Test (2003) 1.09
Management of fibromyalgia and comorbid psychiatric disorders. J Clin Psychiatry (2008) 0.96
Introduction: fibromyalgia and its related disorders. J Clin Psychiatry (2008) 0.87
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord (2008) 9.52
Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord (2012) 5.12
Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med (2004) 4.56
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord (2007) 3.86
A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature (2011) 3.53
The MC1R melanoma risk variant p.R160W is associated with Parkinson disease. Ann Neurol (2015) 2.71
Repetitive transcranial magnetic stimulation for the treatment of depression. Systematic review and meta-analysis. Br J Psychiatry (2003) 2.61
MDS Task Force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI. Mov Disord (2011) 2.27
Long-term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson's disease. Mov Disord (2010) 2.20
Favorable outcome of ischemic stroke in patients pretreated with statins. Stroke (2004) 1.85
Controlled study of decision-making and cognitive impairment in Parkinson's disease. Mov Disord (2007) 1.73
ALAS2 acts as a modifier gene in patients with congenital erythropoietic porphyria. Blood (2011) 1.68
A170P mutation in SHOX gene in a patient not presenting with Madelung deformity. J Clin Pathol (2012) 1.52
Cognitive impairment in Parkinson's disease: tools for diagnosis and assessment. Mov Disord (2009) 1.51
Reproductive consequences of genome-wide paternal uniparental disomy mosaicism: description of two cases with different mechanisms of origin and pregnancy outcomes. Fertil Steril (2009) 1.49
Cut-off score of the Mattis Dementia Rating Scale for screening dementia in Parkinson's disease. Mov Disord (2008) 1.45
Prevalence and correlates of neuropsychiatric symptoms in Parkinson's disease without dementia. Mov Disord (2008) 1.33
Evidence of depressive symptoms in fragile-X syndrome premutated females. Psychiatr Genet (2008) 1.33
Rey verbal learning test is a useful tool for differential diagnosis in the preclinical phase of Alzheimer's disease: comparison with mild cognitive impairment and normal aging. Int J Geriatr Psychiatry (2003) 1.32
A novel elastin gene mutation resulting in an autosomal dominant form of cutis laxa. Arch Dermatol (2004) 1.29
Cognitive impairment and dementia in Parkinson's disease. Neurobiol Dis (2012) 1.26
Dementia risk in Parkinson disease: disentangling the role of MAPT haplotypes. Arch Neurol (2011) 1.23
Role of the CDKN2A locus in patients with multiple primary melanomas. J Clin Oncol (2005) 1.22
Glucocerebrosidase mutations confer a greater risk of dementia during Parkinson's disease course. Mov Disord (2011) 1.15
Dosage-dependent severity of the phenotype in patients with mental retardation due to a recurrent copy-number gain at Xq28 mediated by an unusual recombination. Am J Hum Genet (2009) 1.11
Benefits of total body photography and digital dermatoscopy ("two-step method of digital follow-up") in the early diagnosis of melanoma in patients at high risk for melanoma. J Am Acad Dermatol (2011) 1.09
A novel mutation in JARID1C gene associated with mental retardation. Eur J Hum Genet (2006) 1.07
Long-term effects of pallidal or subthalamic deep brain stimulation on quality of life in Parkinson's disease. Mov Disord (2009) 1.06
Clinical, biochemical, and genetic study of 11 patients with erythropoietic protoporphyria including one with homozygous disease. Arch Dermatol (2007) 1.06
Tremor dominant parkinsonism: Clinical description and LRRK2 mutation screening. Mov Disord (2008) 1.01
Motor laterality asymmetry and nonmotor symptoms in Parkinson's disease. Mov Disord (2010) 1.01
Pattern of regional cortical thinning associated with cognitive deterioration in Parkinson's disease. PLoS One (2013) 1.01
Cognitive impairment in nondemented Parkinson's disease. Mov Disord (2011) 1.01
Transcranial magnetic stimulation of the cerebellum in essential tremor: a controlled study. Arch Neurol (2002) 1.00
Changes in artistic style and behaviour in Parkinson's disease: dopamine and creativity. J Neurol (2009) 0.99
Coamplified and overexpressed genes at ERBB2 locus in gastric cancer. Int J Cancer (2004) 0.98
Benefits of a prehospital stroke code system. Feasibility and efficacy in the first year of clinical practice in Barcelona, Spain. Cerebrovasc Dis (2004) 0.97
Fatal pulmonary Nocardia farcinica infection. J Clin Microbiol (2002) 0.96
A comparison of CDKN2A mutation detection within the Melanoma Genetics Consortium (GenoMEL). Eur J Cancer (2008) 0.95
Correlation among dermoscopy, confocal reflectance microscopy, and histologic features of melanoma and basal cell carcinoma collision tumor. Dermatol Surg (2011) 0.95
15q11.2 microdeletion and FMR1 premutation in a family with intellectual disabilities and autism. Gene (2012) 0.95
Homocysteine and cognitive impairment in Parkinson's disease: a biochemical, neuroimaging, and genetic study. Mov Disord (2009) 0.94
Molecular analysis of the APC and MUTYH genes in Galician and Catalonian FAP families: a different spectrum of mutations? BMC Med Genet (2009) 0.94
PCA3 in the detection and management of early prostate cancer. Tumour Biol (2013) 0.94
MLPA as first screening method for the detection of microduplications and microdeletions in patients with X-linked mental retardation. Genet Med (2007) 0.92
Effects of pallidotomy and bilateral subthalamic stimulation on cognitive function in Parkinson disease. A controlled comparative study. J Neurol (2003) 0.92
Screening for FXTAS in 95 Spanish patients negative for Huntington disease. Genet Test (2008) 0.91
Xq26.2-q26.3 microduplication in two brothers with intellectual disabilities: clinical and molecular characterization. J Hum Genet (2010) 0.91
Measuring functional impact of cognitive impairment: validation of the Parkinson's disease cognitive functional rating scale. Parkinsonism Relat Disord (2013) 0.90
REM sleep behavior disorder and vocal cord paralysis in Machado-Joseph disease. Mov Disord (2003) 0.90
Premature ovarian failure and fragile X female premutation carriers: no evidence for a skewed X-chromosome inactivation pattern. Menopause (2009) 0.90
X-inactivation of HSD17B10 revealed by cDNA analysis in two female patients with 17β-hydroxysteroid dehydrogenase 10 deficiency. Eur J Hum Genet (2010) 0.90
Does thrombolysis benefit patients with lacunar syndrome? Eur Neurol (2006) 0.90
Selecting deep brain stimulation or infusion therapies in advanced Parkinson's disease: an evidence-based review. J Neurol (2013) 0.90
Structure and regulation of the versican promoter: the versican promoter is regulated by AP-1 and TCF transcription factors in invasive human melanoma cells. J Biol Chem (2009) 0.89
The tools of the trade: a state of the art "How to Assess Cognition" in the patient with Parkinson's disease. Mov Disord (2014) 0.89
Usefulness of p300 in subjective memory complaints: a prospective study. J Clin Neurophysiol (2005) 0.89
Neuropsychological correlates of mild to severe hallucinations in Parkinson's disease. Mov Disord (2010) 0.88
Studies of complex Ph translocations in cases with chronic myelogenous leukemia and one with acute lymphoblastic leukemia. Cancer Genet Cytogenet (2006) 0.88
Cutaneous phenotype and MC1R variants as modifying factors for the development of melanoma in CDKN2A G101W mutation carriers from 4 countries. Int J Cancer (2007) 0.88
Common genetic background in anorexia nervosa and obsessive compulsive disorder: preliminary results from an association study. J Psychiatr Res (2013) 0.88
Diagnosis and management of essential tremor and dystonic tremor. Ther Adv Neurol Disord (2009) 0.87
Predicting dementia development in Parkinson's disease using Bayesian network classifiers. Psychiatry Res (2012) 0.87
Semantic knowledge of famous people in mild cognitive impairment and progression to Alzheimer's disease. Dement Geriatr Cogn Disord (2004) 0.86
Routine neurophysiologic tremor analysis as a diagnostic tool for essential tremor: a prospective study. J Clin Neurophysiol (2004) 0.86
Comorbid Asperger and Tourette syndromes with localized mesencephalic, infrathalamic, thalamic, and striatal damage. Dev Med Child Neurol (2003) 0.86
Apathy in Parkinson's disease: neurophysiological evidence of impaired incentive processing. J Neurosci (2014) 0.86
Acute effects of immediate and controlled-release levodopa on mood in Parkinson's disease: A double-blind study. Mov Disord (2007) 0.85
A parallel study of different array-CGH platforms in a set of Spanish patients with developmental delay and intellectual disability. Gene (2013) 0.85
Novel MLH1 duplication identified in Colombian families with Lynch syndrome. Genet Med (2011) 0.84
Parkinson's disease-cognitive rating scale: psychometrics for mild cognitive impairment. Mov Disord (2013) 0.84
Genetic alterations in RAS-regulated pathway in acral lentiginous melanoma. Exp Dermatol (2013) 0.84
PDD-Short Screen: a brief cognitive test for screening dementia in Parkinson's disease. Mov Disord (2010) 0.84
Capturing the biological impact of CDKN2A and MC1R genes as an early predisposing event in melanoma and non melanoma skin cancer. Oncotarget (2014) 0.84
Is all cognitive impairment in Parkinson's disease "mild cognitive impairment"? J Neural Transm (Vienna) (2011) 0.83
Apathy in Parkinson's disease: more than just executive dysfunction. J Int Neuropsychol Soc (2013) 0.83